Bright Minds Biosciences Inc. fell 52.3% on Monday, November 2, 2026, on 1,826,624 shares, 14 times its average daily volume. Headlines around the move:
Bright Minds Biosciences Inc. (DRUG:NASDAQ) closed at $26.20 on November 2, 2026, down 52.35% on the day. The stock trades 78.8% below its 52-week high of $123.75 and 38.6% above its 52-week low of $18.90. Over the past year, it lost 48.9%. Bright Minds Biosciences Inc. is part of the Health Care sector.
In 252 trading sessions since October 31, 2025, DRUG closed higher on 118 days (47%). Its best day was January 6, 2026 (+16.50%) and its worst was November 2, 2026 (-52.35%). The stock moved 10% or more in a single session 6 times. It opened at least 5% above the previous day's high 1 time.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
Find more stocks like DRUG with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.